Anticancer effect of docetaxel/hydroxypropyl-beta-cyclodextrin complex without histamine release

Abstract

In this study, the anticancer effect and improved safety for hypesensitivity reactions of docetaxel/hydroxypropyl-beta-cyclodextrin complex (DCX-CD) were investigated. The preparation of DCX-CD was confirmed by using differential scanning calorimetry, X-ray powder diffraction analysis, and scanning electron microscope. The anticancer activity was tested in human lung cancer A549 cell-transplanted mice and the hypersensitivity was tested in Beagle dogs after intravenous administration of DCX-CD, Taxotere, and their respective vehicles. In the hypersensitivity test, plasma histamine levels were determined using an ELISA method. Our results showed that DCX-CD was pharmacologically equivalent to Taxotere. Furthermore, DCX-CD did not cause the release of histamines or any significant symptoms associated with hypersensitivity. These results suggested that DCX-CD could be a promising alternative to Taxotere for cancer chemotherapy with reduced side effects.